# US 2025/0369983 A1 · Compositions and methods for optimized igg production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0369983 A1
- Document ID: US20250369983A1
- Status: Published application
- Kind: A1
- Application number: 19/221,094
- Filed: 2025-05-28
- Published: 2025-12-04
- Earliest claimed: 2024-06-02
- Applicants: Abbratech, Inc.
- Inventors: Michael P. Weiner
- Web page: https://patentgrep.com/patent/US20250369983A1

## CPC

- A61K 39/12: Viral antigens
- G01N 33/6857: {Antibody fragments}
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61P 31/18: for HIV
- C07K 16/114: Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 5/0635: {B lymphocytes}
- C12N 15/1034: {Isolating an individual clone by screening libraries}
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- A61K 2039/6031: {Proteins}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a method of producing an antigen-binding protein (e.g., antigen-binding region, immunoglobulin, or antigen-binding fragment thereof), including cloning from a single B-cell at least one immunoglobulin heavy chain or an antigen-binding fragment thereof and at least one immunoglobulin light chain or an antigen-binding fragment thereof; producing at least one antigen-binding protein expressing host cell that expresses one or more of a single antigen-binding protein comprising one of the at least one immunoglobulin heavy chain or antigen-binding fragment thereof and one of the at least one immunoglobulin light chain or antigen-binding fragment thereof; screening/examining each of the at least one antigen-binding protein expressing host cell for the specificity, avidity, and/or affinity of the antigen-binding protein for a protein or peptide epitope of interest to find or select at least one antigen-binding protein; and expressing the at least one antigen-binding protein of interest in a eukaryotic cell.

## Claims

### Claim 1

A method of producing a homogenous antigen-binding protein, the method comprising:
cloning from a single B-cell or B-lymphocyte (I) at least one immunoglobulin (Ig) heavy chain or an antigen-binding fragment thereof and (II) at least one immunoglobulin (Ig) light chain or an antigen-binding fragment thereof;
producing at least one antigen-binding protein containing host cell that expresses one or more of a single antigen-binding protein comprising one of the at least one immunoglobulin (Ig) heavy chain or an antigen-binding fragment thereof and one of the at least one immunoglobulin (Ig) light chain or an antigen-binding fragment thereof;
screening or examining each of the at least one antigen-binding protein containing host cell for at least one of specificity, avidity, affinity, or a combination thereof, of the antigen-binding protein for a protein or peptide epitope of interest to find or select at least one antigen-binding protein; and
expressing the at least one antigen-binding protein in a eukaryotic cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein cloning from a single B-cell or B-lymphocyte (I) at least one immunoglobulin (Ig) heavy chain and (II) at least one immunoglobulin (Ig) light chain comprises at least one of:
(a) cloning the at least one immunoglobulin (Ig) heavy chain or an antigen-binding fragment or portion thereof into a first expression vector to produce at least one heavy chain expression vector or construct;
(b) cloning the at least one immunoglobulin (Ig) light chain or an antigen-binding fragment or portion thereof into a second expression vector to produce at least one light chain expression vector or construct; or
(c) a combination thereof.

### Claim 3 (depends on 2)

The method of claim 2, further comprises at least one of:
isolating and/or extracting the at least one heavy chain expression vector;
isolating and/or extracting the at least one light chain expression vector; or
a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein at least one of:
producing at least one antigen-binding protein containing host cell that expresses one or more of a single antigen-binding protein comprising pairing each of the plurality of immunoglobulin (Ig) heavy chain or an antigen-binding fragment thereof with each of the plurality of immunoglobulin (Ig) light chain or an antigen-binding fragment thereof to produce a plurality of antigen-binding protein containing host cell that expresses a single antigen-binding protein;
expressing the at least one antigen-binding protein further comprises amplifying the expression vector or expression vectors in a bacterial cell;
the method further comprises isolating or extracting the expression vector or expression vectors for each of the at least one antigen-binding protein from the transformed bacterial cell;
expressing the at least one antigen-binding protein further comprises transfecting the eukaryotic cell with the expression vector or expression vectors;
(i) the first expression vector and the second expression vector have the same sequence or (ii) the first expression vector and the second expression vector have different sequences; or
a combination thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein producing at least one antigen-binding protein containing host cell comprises:
transforming each of the at least one heavy chain expression vector into an individual host cell to produce at least one heavy chain containing host cell;
transforming each of the at least one light chain expression vector into an individual host cell to produce at least one light chain containing host cell; and
mating one of the at least one heavy chain containing host cell and one of the at least one light chain containing host cell, and optionally integrating the heavy chain expression vector and the light chain expression vector in the at least one antigen-binding protein containing host cel.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, further comprising prior to cloning from a single B-cell or B-lymphocyte, selecting and/or isolating a B-cell or B-lymphocyte expressing CD19 and that binds the protein or peptide epitope of interest.

### Claim 8 (depends on 7)

The method of claim 7, wherein selecting or isolating a B-cell or B-lymphocyte comprises selecting or isolating a naïve B cell, a memory B-cell, or a plasma cell that binds the protein or peptide epitope of interest.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein screening or examining each of the at least one antigen-binding protein containing host cell for the specificity, the avidity, the affinity, or a combination thereof, of the antigen-binding protein comprises:
providing a set of fusion proteins that comprises two or more fusion proteins, wherein:
each fusion protein includes a maltose-binding protein, or amylose-binding derivative thereof, fuses directly to or via a linker to a target sequence of about 8 amino acids to 18 amino acids from the protein or peptide epitope of interest; and
each target sequence of the set of fusion proteins has a different proteinogenic amino acid at a site of interest in the target sequence, including (i) one that has the native amino acid of the target sequence or (ii) one or more has a native amino acid when the site of interest is a variant site; and
examining or detecting which of the fusion proteins that the antigen-binding protein binds.

### Claim 11 (depends on 10)

The method of claim 10, wherein at least one of:
detecting is performed via an enzyme-linked immunosorbent assay, and each fusion protein is a different antigen of the enzyme-linked immunosorbent assay;
the maltose-binding protein derivative has been engineered/modified to provide tighter binding to amylose resin;
the linker is a protein linker;
the linker is a protein linker, wherein the protein linker includes or consists of about 1 to about 10 amino acids;
the target sequence is linked to the C-terminus of the maltose-binding protein;
the set of fusion proteins includes a fusion protein comprising a target sequence for two or more variant of the protein or peptide epitope of interest; or
a combination thereof.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 11)

The method of claim 11, wherein (i) the antigen-binding protein binds to a specific variant of the protein or peptide epitope of interest, or (ii) the antigen-binding protein binds to a specific set of variants of the protein or peptide epitope of interest.

### Claim 15 (depends on 10)

The method of claim 10, wherein at least one of:
the antigen-binding protein binds to only a target sequence with the native amino acid at the site of interest;
the method further comprising expressing each fusion protein via an expression vector or construct that expresses the fusion protein;
the method further comprising purifying each fusion protein from a cell in which it was expressed; or
a combination thereof.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The method of claim 15, wherein purifying comprises, for one or more of the fusion proteins, at least one of:
adding a cell lysate containing the fusion protein to a gravity flow column comprising amylose resin;
optionally washing the gravity flow column after the cell lysate is added;
eluting and/or collecting the fusion protein; or
a combination thereof.

### Claim 18 (depends on 10)

The method of claim 10, further comprising determining or quantifying the lower limit of detection of the antigen-binding protein by examining the protein or peptide epitope of interest at a plurality of concentrations.

### Claim 19 (depends on 1)

The method of claim 1, further comprising generating the B-cell or B-lymphocyte.

### Claim 20 (depends on 19)

The method of claim 19, wherein generating the B-cell or B-lymphocyte comprises:
a. immunizing an animal at least once with a modified peptide having an amino acid sequence of about 8 to about 20 amino acids identical to an amino acid sequence of the protein or peptide epitope of interest that includes the amino acids of the target sequence, except wherein one internal amino acid has been substituted with a non-native amino acid (nnAA);
b. boosting the animal at least once with a first unmodified peptide comprising a core amino acid sequence identical to the modified peptide of step (a), except wherein the nnAA has been substituted with the native amino acid (nAA), a first N-terminal amino acid sequence that is not native to the protein or peptide epitope of interest, and a first C-terminal amino acid sequence that is not native to the protein or peptide epitope of interest.

### Claim 21 (depends on 20)

The method of claim 20, further comprising:
c. cloning B-cells obtained from the animal; and
d. identifying a clone of step (c) that:
i. binds to the first unmodified peptide and a second unmodified peptide comprising a core amino acid sequence that is identical to the first unmodified peptide, a second N-terminal amino acid sequence that is not native to the protein or peptide epitope of interest, and a second C-terminal amino acid sequence that is not native to the protein or peptide epitope of interest; and
ii. does not bind to the modified peptide of step (a).

### Claim 22 (depends on 21)

The method of claim 21, further comprising identifying a clone that binds to the protein or peptide epitope of interest.

### Claim 23

(canceled)

### Claim 24 (depends on 20)

The method of claim 20, wherein at least one of:
the animal is a human, a rabbit, a mouse, a rat, a goat, a cow, a pig, a camelid, or a chicken;
the animal is a non-human animal that has a human or humanized immune system;
the modified peptide, the first unmodified peptide, the second unmodified peptide, or a combination thereof, is administered with an adjuvant;
the modified peptide is conjugated to one or more carriers, the first unmodified peptide is conjugated to one or more carriers, or a combination thereof; or
a combination thereof.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 19)

The method of claim 19, wherein generating the B-cell or B-lymphocyte comprises:
a. providing a modified peptide having an amino acid sequence of about 8 to about 20 amino acids identical to an amino acid sequence of the protein or peptide epitope of interest and includes the amino acids of the target sequence, except wherein the wild-type amino acid at the site of interest has been substituted with a non-native amino acid (nnAA);
b. screening the modified peptides against a library;
c. isolating one or more binding agents that bind to the modified peptide;
d. generating a library of clonotypes of the one or more binding agents isolated in step (c);
e. screening the library of clonotypes against:
i. the modified peptide of step (a); and
ii. a first unmodified peptide comprising a core amino acid sequence identical to the modified peptide of step (a), except wherein the non-native amino acid (nnAA) has been substituted with the wild-type amino acid (nAA), a first N-terminal amino acid sequence that is not native to the protein or peptide epitope of interest and a first C-terminal amino acid sequence that is not native to the protein or peptide epitope of interest; and
f. isolating a binding agent that bind to both the first unmodified peptide and the modified peptide, wherein the binding agent is the antigen-binding protein (e.g., antibody or an antigen-binding fragment or portion thereof) or derived therefrom.

### Claim 29 (depends on 19)

The method of claim 19, wherein generating the B-cell or B-lymphocyte comprises:
a. providing a modified peptide having an amino acid sequence of about 8 to about 20 amino acids identical to an amino acid sequence of the protein or peptide epitope of interest and includes the amino acids of the target sequence, except wherein the wild-type amino acid at the site of interest has been substituted with a non-native amino acid (nnAA);
b. screening the modified peptides against a library;
c. isolating one or more binding agents that bind to the modified peptide;
d. generating a library of clonotypes of the one or more binding agents isolated in step (c);
e. screening the library of clonotypes against:
i. the modified peptide of step (a); and
ii. a first unmodified peptide comprising a core amino acid sequence identical to the modified peptide of step (a), except wherein the non-native amino acid (nnAA) has been substituted with the wild-type amino acid (nAA), a first N-terminal amino acid sequence that is not native to the protein or peptide epitope of interest and a first C-terminal amino acid sequence that is not native to the protein or peptide epitope of interest;
f. isolating a binding agent that bind to both the first unmodified peptide and the modified peptide;
g. generating a library of clonotypes of the binding agent isolated in step (f);
h. screening the library of clonotypes of step (g) against:
i. the modified peptide;
ii. the first unmodified peptide; and
iii. a second unmodified peptide comprising a core amino acid sequence that is identical to the first unmodified peptide, a second N-terminal amino acid sequence that is not native to the protein or peptide epitope of interest, and a second C-terminal amino acid sequence that is not native to the protein or peptide epitope of interest; and
f. isolating a binding agent that binds to the first unmodified peptide and the second unmodified peptide, wherein the binding agent does not bind the modified peptide, and the binding agent is the antigen-binding protein or derived therefrom.

### Claim 30 (depends on 19)

The method of claim 19, wherein generating the B-cell or B-lymphocyte comprises:
a. providing a modified peptide having an amino acid sequence of about 8 to about 20 amino acids identical to an amino acid sequence of the protein or peptide epitope of interest and includes the amino acids of the target sequence, except wherein the wild-type amino acid at the site of interest has been substituted with a non-native amino acid (nnAA);
b. screening the modified peptides against a library;
c. isolating one or more binding agents that bind to the modified peptide;
d. generating a library of clonotypes of the one or more binding agents isolated in step (c);
e. screening the library of clonotypes against:
i. the modified peptide of step (a); and
ii. a first unmodified peptide comprising a core amino acid sequence identical to the modified peptide of step (a), except wherein the non-native amino acid (nnAA) has been substituted with the wild-type amino acid (nAA), a first N-terminal amino acid sequence that is not native to the protein or peptide epitope of interest and a first C-terminal amino acid sequence that is not native to the protein or peptide epitope of interest;
f. isolating a binding agent that bind to both the first unmodified peptide and the modified peptide;
g. generating a library of clonotypes of the binding agent isolated in step (f);
h. screening the library of clonotypes of step (g) against:
i. the modified peptide;
ii. the first unmodified peptide; and
iii. a second unmodified peptide comprising a core amino acid sequence that is identical to the first unmodified peptide, except wherein the wild-type amino acid (nAA) has been substituted with an amino acid corresponding to a variant, a second N-terminal amino acid sequence that is not native to the protein or peptide epitope of interest and a second C-terminal amino acid sequence that is not native to the protein or peptide epitope of interest; and
i. isolating a binding agent that binds to the second unmodified peptide and does not bind the first modified peptide, wherein the binding agent is the antigen-binding protein or derived therefrom.

### Claim 31 (depends on 20)

The method of claim 20, wherein at least one of:
the non-native amino acid (nnAA) is offset from or relative to the site of interest;
the non-native amino acid (nnAA) is a non-synonymous amino acid;
the non-native amino acid (nnAA) is phosphorylated, acetylated, isocyanated, sulfated, or nitrated;
the non-native amino acid (nnAA) acid is O-phosphoserine (SEP), phosphotyrosine, or phosphothreonine;
the N-terminal amino acid sequence is SerGlySer, GlySerGly, GlyGlyGly, or SerSerSer;
the C-terminal amino acid sequence is SerGlySer, GlySerGly, GlyGlyGly, or SerSerSer; or
a combination thereof.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)
